Immune checkpoint-based immunotherapies have been incorporated, albeit to a limited extent, into treatment modalities for some other cancers, but clinical trials targeting checkpoint molecules, such as CTLA4, PD-1/PD-L1, or their other cognate ligands have been unsuccessful for the treatment of PDAC. The gene discussed is CD274; the disease is cancer.